Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 3, 2013

X-Chem, AstraZeneca Expand Drug Discovery Collab

  • Small molecule-focused drug discovery firm X-Chem has entered into an expanded global drug discovery collaboration with AstraZeneca across all of the pharmaceutical company’s therapeutic areas and multiple target classes.

    The companies entered into a previous collaboration in May of 2012. This new agreement comes just weeks after AstraZeneca elected to license three drug discovery programs resulting from that 2012 effort, directed at an oncology protein-protein interaction target, a respiratory/inflammation PPI target, and an antibacterial target. AstraZeneca has opted to extend the initial research collaboration from two to five years, and X-Chem will conduct drug discovery on at least 10 therapeutic targets per year going forward.

    Per the new agreement, X-Chem will receive committed research and development funding for each project, and each X-Chem program licensed by AstraZeneca is eligible for preclinical, clinical, and sales milestones in the aggregate amount of up to $26 million. In addition, X-Chem will receive royalties for each successfully commercialized drug that results from a licensed collaboration program.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »